AstraZeneca’s Q2 results lacked lustre, coming largely in line with our expectations, with the outperformance of product sales of $5.5bn being truncated by lower externalisation revenue, netting sales of $5.6bn. This represented a decline of 10% yoy (NB all revenue growth numbers at constant currency unless specified otherwise), emanating primarily from the Crestor (-29%) and Nexium (-13%) side of the business in the US. Currency had an adverse impact of 100bp. Cost containment, however
30 Aug 2016
A quarter of Brilinta, Farxiga and oncology
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A quarter of Brilinta, Farxiga and oncology
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
30 Aug 2016 -
Author:
Kamla Singh -
Pages:
4
AstraZeneca’s Q2 results lacked lustre, coming largely in line with our expectations, with the outperformance of product sales of $5.5bn being truncated by lower externalisation revenue, netting sales of $5.6bn. This represented a decline of 10% yoy (NB all revenue growth numbers at constant currency unless specified otherwise), emanating primarily from the Crestor (-29%) and Nexium (-13%) side of the business in the US. Currency had an adverse impact of 100bp. Cost containment, however